Engineering GVL through T cell gene transfer.
Jensen
Michael C
MC
Division of Cancer Immunotherapeutics & Tumor Immunology, Beckman Research Institute of City of Hope, Duarte, California, USA. mjensen@coh.org
D019264:Adoptive Transfer; D018941:Antigens, CD19 / Q000276:immunology; D018951:Antigens, CD20 / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology / Q000473:pathology; D020544:Graft vs Leukemia Effect / Q000187:drug effects*; D006801:Humans; D015448:Leukemia, B-Cell / Q000628:therapy*; D016393:Lymphoma, B-Cell / Q000628:therapy*; D015202:Protein Engineering / Q000379:methods*; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000627:therapeutic use*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology* / Q000637:transplantation
D018941:Antigens, CD19; D018951:Antigens, CD20; D011993:Recombinant Fusion Proteins